GlassScriptPhysician profile
Brian L Allen
NPI 1275598278
$14,133.75
in general payments reported to CMS, 2019-2025
42 companies · $2,363 in 2025
The $2,363 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $1,517 · 2021: $1,808 · 2022: $2,168 · 2023: $2,377 · 2024: $2,429 · 2025: $2,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,168.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,501.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,323.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,232.37 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Astrazeneca Pharmaceuticals LP | $1,111.69 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $975.08 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $894.76 | 2019-2025 | |
| Amgen INC. | $861.74 | 2019-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $780.15 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Abbott Laboratories | $759.55 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $435.98 | 2019-2024 | Verquvo, Belsomra, Januvia |
| Takeda Pharmaceuticals U.S.A., INC. | $317.65 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $302.28 | 2019-2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $289.49 | 2022-2025 | |
| Astellas Pharma US INC | $279.90 | 2019-2025 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $241.78 | 2024-2025 | Caplyta |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.